Revive Therapeutics (CSE: RVV) (OTC: RVVTF) is one step closer to conducting its phase 3 clinical trials for the use of Bucillamine in the treatment of COVID-19. The company announced this morning that it has signed a memorandum of understanding with Attwill Medical Solutions Sterilflow, LP to establish the firm as a resource for clinical … Continue reading Revive Therapeutics Signs MOU With Attwill Medical, Manufacturer For Vaxart, For Phase 3 Clinical Trials